Treatment of Idiopathic Pulmonary Fibrosis with Losartan: A Pilot Project
- 385 Downloads
Idiopathic pulmonary fibrosis is a progressive interstitial lung disease with no current effective therapies. Treatment has focused on antifibrotic agents to stop proliferation of fibroblasts and collagen deposition in the lung. We present the first clinical trial data on the use of losartan, an antifibrotic agent, to treat idiopathic pulmonary fibrosis. The primary objective was to evaluate the effect of losartan on progression of idiopathic pulmonary fibrosis measured by the change in percentage of predicted forced vital capacity (%FVC) after 12 months. Secondary outcomes included the change in forced expiratory volume at 1 second, diffusing capacity of carbon monoxide, 6-minute walk test distance, and baseline/transition dyspnea index.
Patients with idiopathic pulmonary fibrosis and a baseline %FVC of ≥50 % were treated with losartan 50 mg by mouth daily for 12 months. Pulmonary function testing, 6-minute walk, and breathlessness indices were measured every 3 months.
Twenty participants with idiopathic pulmonary fibrosis were enrolled and 17 patients were evaluable for response. Twelve patients had a stable or improved %FVC at study month 12. Similar findings were observed in secondary end-point measures, including 58, 71, and 65 % of patients with stable or improved forced expiratory volume at 1 second, diffusing capacity for carbon monoxide, and 6-minute walk test distance, respectively. No treatment-related adverse events that resulted in early study discontinuation were reported.
Losartan stabilized lung function in patients with idiopathic pulmonary fibrosis over 12 months. Losartan is a promising agent for the treatment of idiopathic pulmonary fibrosis and has a low toxicity profile.
KeywordsPulmonary fibrosis Angiotensin receptor blocker Forced vital capacity Dyspnea Six-minute walk test
This work was supported by the SunCoast CCOP Research Base (award No. U10CA081920 from the National Cancer Institute). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health.
Conflict of interest
The authors have no conflicts of interest or financial ties to disclose.
The experiment complies with the current laws of the United States of America.
- 1.ATS/ERS (2000) Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. Am J Respir Crit Care Med 161(2 Pt 1):646–664Google Scholar
- 5.Papp M, Li X, Zhuang J et al (2002) Angiotensin receptor subtype AT(1) mediates alveolar epithelial cell apoptosis in response to ANG II. Am J Physiol Lung Cell Mol Physiol 282:L714–L718Google Scholar
- 17.Liang X, Xie X, Yang T, Sun M, Zhao S (2002) Apoptosis, myocardial fibrosis and angiotensin II in the left ventricle of hypertensive rats treated with fosinopril or losartan. Chin Med J (Engl) 115(9):1287–1291Google Scholar
- 20.Shibasaki Y, Nishiue T, Masaki H, Tamura K, Matsumoto N, Mori Y et al (2005) Impact of the angiotensin II receptor antagonist, losartan, on myocardial fibrosis in patients with end-stage renal disease: assessment by ultrasonic integrated backscatter and biochemical markers. Hypertens Res 28:787–795PubMedCrossRefGoogle Scholar
- 21.Díez J, Querejeta R, López B, González A, Larman M, Martínez Ubago JL (2002) Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 106(25):12–17Google Scholar
- 26.López G, Querejeta R, Larman M, Díez J (2005) Myocardial COX-2 overexpression and fibrosis in hypertensive heart disease. Am J Hypertens 18(5 Pt 2):A223–A233Google Scholar